بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قال الله تعالى

وَقُلْ رَبِّ زِدْنِي عِلْمًا

صدق الله العظيم

سورة طه الآية 114

Decation

To my dear family

And

To all diabetes Mellitus patients

Acknowledgement

All my gratitude and respect to Dr. Adil Mahgoub Ibrahim (Department of biochemistry, college of medical laboratory science, Sudan university of science and technology), for his supervision, time, patience, effort, critical comments and discussion concerning my research study.

My very special thanks and respect to Dr. Mohammed Abdelraheem Abdalla (Department of biochemistry, college of medical laboratory science, Sudan university of science and technology), for his help, lead and make a successfully for my thesis.

I would like to thank all those offered me their assistance, and help me to success this study in whatever needed.

My thanks extended to the laboratory members of Jabir Abu Alizz center for their assistance in collection of samples from the patients.

My special thanks to Ustaz Badr Addinn Musa Ahmed and Ustaz Mohammed Seddig Abdelaziz (Sudan university of science and technology, College of medical laboratory science) for their help and facilities during this study.

ABSTRACT

Atherosclerotic cardiovascular diseases (CVD) are the major causes of mortality in patients with diabetes mellitus. Both quantitative and qualitative abnormalities of lipoproteins were associated with the development of atherogenesis. In this study we concluded to essentially investigated apolipoprotein as a good diagnostic marker for atherosclerosis. A randomly selected 60 Sudanese diabetic patients (30 type1, 30 type2) visited Jabir Abu Alizz Diabetes Centre (Khartoum, Central Sudan) were enrolled in the study during July-September 2005. A total number of 30 healthy volunteered individuals as a control group. Blood specimens were collected from all groups (n = 90) and serum lipid, lipid profiles and Apolipoprotein were determined. Statistical analysis was done, using SPSS package descriptive and comparing different parameters between groups of patients and control.

According to assessment blood glucose was increased in patients compared to control (p<0.05), the leve of total cholesterol in patients were: 8% (n = 5) a high level, 8% (n= 5) high normal and 84% (n =50) had a normal level. However no significance in the assessment of triglyceride and VLDL in patients and controls, although there were 5% (n=3) of patients had a high level of both. The study indicated a significance increased (p<0.05) the level of Apolipoprotein B, lipoprotein(a) and LDL cholesterol in patients group compared to controls, [about 15% (n=9) of patients had a high normal level Apo B, 12% (n=7) of patients had a high normal level LDL, and 73% (n= 44) [38% (n= 23) type1, & 35% (n= 21) type2], of patients had a high level of Lp(a) than controls]; where in the other hand the level of Apolipoprotein A1 and HDL cholesterol, were significantly increased in controls compared to patients group, [10% (n= 6) of patients were low normal HDL level and also 21% (n= 13) of Apo A1]. The study indicated that there were a significance correlation between apolipoprotein B, LDL cholesterol and Lp(a), and apolipoprotein A1 and HDL cholesterol (p<0.01). The study indicated that lipo(a) and Apo B were increased when compared within group of patients, and it increased in type 1DM compare to type2 DM. The study also concluded to that Lp(a), was increased proprtionally with the age of patients.

In conclusion the study confirmed that Apolipoprotein is an important diagnostic marker that can be used for early detection of atherosclerotic cardiovascular disease (CVD) in diabetic patients and follow up of patients, particularly when such information cannot be obtained by use of routine lipid profiles examination.

ملخص الدراسة

تعتبر أمراض تصلب الشرايين وأمراض القلب من أهم أسباب الوفاة عند مرضى السكري , والتقدير النوعي والكمي للدهون يؤكد ذلك. وهذه الدراسة خلصت إلى ضرورة استعمال الابوليبوبروتين كمؤشر جيد للتشخيص.

تم في هذه الدراسة اختيار مجموعة من 60 مريضا بالسكري يعالجون في مركز جابر أبو العز لمرضى السكر , في الفترة من يوليو - سبتمبر 2005م , و قد تم تقسيم المرضى إلى مجموعتين, مجموعة تضم 30 مريضا وتسمى مرضى السكر قسم 1 يعالجون بالأنسولين وأخرى تضم نفس العدد وتسمى مرضى السكر قسم 2 لا يعالجون بالأنسولين. كما أخذت عينات من 30 متطوعا أصحاء كعينات مرجعية لمقارنة النتائج. وقد تم اخذ عينات دم من كل المجموعات قيست فيها نسب الدهون ومشتقاتها والابوليبوبروتين , وباستعمال التحليل الاحصائى ((SPSS قورنت النتائج بين المجموعات.

وقد وجدت نسبة الجلوكوز مرتفعة جدا عند المرضى مقارنة بالأصحاءِ عند احتمال احصائي (p<0.05) , أما نسبة الكولسترول وجدت أيضا مرتفعة عند%8 (5)من المرضى, %8 (5) في اعلى المستوى الطبيعي و%84 (50) في المستوى الطبيعي. ولكن لم يوجد فرق كبير في نسبتي الدهون الثلاثية triglyceride)) والدهون ذات الكثافة القليلة جدا (VLDL) بين المرضى والأصحاء بالرغم من وجود 5% (3) من المرضى معدل للاثنين عندهم مرتفع. كما أثبتت الدراسة ان الابوليبوبروتين (B), الليبوبروتين الصغير (Lp(a))} والليبوبروتين ذو الكثافة الأقل (LDL) مرتفعة عند المرضى من المجموعتين مقارنة بالأصحاء بدلالة إحصائية (p<0.05) {حوالي % $^{\circ}$ مرتفع و $^{\circ}$ LDL (7)12% مرتفع و B مرتفع و LDL (7)12% من المرضى مستوى (44)73),]38%(23) قسم 1, %35(21) قسم 2 [من المرضى مستوى Lp(a) اكثر من الاصحاء}. كما في الناحية الأخرى فان الابوليبوبروتين (A1) والليبوبروتين ذو الكثافة الأعلى (HDL) قد وجدت نسبته أعلى عند الأصحاء مقارنة بالمرضى {HDL (6)10%, و%21(13) A1 من المرضى أقل من الاصحاء. وقد أشارت الدراسة لُوجود علاقة ارتباطً بين الابوليبوبروتين (B), (LDL) وأيضاً بين $\sim p)$ كل من الابوليبوبروتين (A1) و (HDL) بدلالة إحصائية (O.01) كل من الابوليبوبروتين (A1) و

وأشارت الدراسة لان متوسط الابوليبوبروتين (B) والليبوبروتين الصغير (a) مرتفع عند المرضى من قسم 1 مقارنة بالمرضى من قسم 2. وخلصت الدراسة ايضا لان معدل الليبوبروتين الصغير (a) في المرضى يزيد طرديا بزيادة العمر.

وفى الختام تخلص الدراسة بصورة عامة إلى إن قياس الابوليبوبروتين مؤشر مهم في تشخيص مرضى السكر بتصلب الشرايين وأمراض القلب في المراحل الأولية خصوصا عندما لا يستطيع تحليل الدهون الأخرى ومشتقاتها إثبات ذلك.

CONTENTS

Topic	Page
Verse	I.
Dedication	II.
Acknowledgement	III.
English Abstract	IV.
Arabic Abstract	V.
Contents	VI.
List of figures	VIII
List of tables	IX
Abbreviations	X
CHAPTER ONE	
INTRODUCTION AND LITERATURE REVIEW	
I. Diabetes mellitus	1
I.1 Biochemistry of diabetes mellitus	2
1.1.1 Types of diabetes mellitus	2
I.1.1.1 Type 1 diabetes mellitus	2
I.1.1.2 Type 2 diabetes mellitus	2
I.1.2 Diagnosis of diabetes mellitus	4
I.1.2.1 Criteria for diagnosis	5
I.1.2.2 Impact of the New Diagnostic Criteria	6
I.1.2.3 Glycated Hemoglobin	7
I.1.2.4 Screening Recommendations	7
I.1.3 Signs and symptoms	8
I.1.3.1 Diabetic ketoacidosis and coma	9
I.1.3.2 Hyperosmotic diabetic coma	10
I.1.3.3 Hypoglycemia	10
I.1.3.4 Long term complications	11
I.1.4 Management of diabetes mellitus	11
I.1.4.1 Monitoring	12
I.2 Apolipoprotein	13
I.2.1 Apolipoprotein AI (Apo A1)	16
I.2.2 Apolipoprotein B (Apo B)	17
1.2.3 Lipoprotein(a) [Lp(a)]	18
1.3 Objectives of this study	21
Chapter Two.	•
SUBJECTS & METHODS	
II.1 Subjects	22
II.2 Sample collection	22
II.3 Methods	22
II.3.1 Determination of blood glucose level	22
II.3.2 Estimation of total Cholesterol	23
II.3.3 Estimation of Triglyceride	24
II.3.4 Estimation of High Density Lipoprotein Cholesterol	24
(HDL-c)	
IL3.5 Estimation of Low Density Lipoprotein Cholesterol	25

(LDL-c)	
II.3.6 Calculation of VLDL	26
II.3.7 Estimation of Apolipoprotein A1	26
II.3.8 Estimation of Apolipoprotein B	27
II.3.9 Estimation of Lipoprotein(a)	27
II.3.10 Statistical Analysis	28
Chapter Three	
Results	
Study Groups	29
Chapter Four	
IV.1 Discussion,	42
IV.2.1 Conclusion	46
IV.2.2 Recommendations	47
V. References	48
Appendices	53

LIST OF FIGURES

Figure	Title	Page
III.1	Fig. III.1 revealed a comparison between mean level of glucose in study :both groups of patient (DM1&DM2) with control subjects	32
III.2	Fig. III.2 explained compared a mean level of total cholesterol in study :both groups of patient (DM1&DM2) with control subjects	33
III.3	Fig. III.3 showed a mean level of triglyceride and VLDL in study both groups of patient (DM1&DM2) in compared with control subject	35
III.4	Fig. III.4 showed a mean level of HDL and LDL in study both groups of :patient (DM1&DM2) in compared with control subjects	37
III.5	Fig. III.5 showed a mean level of Apo A1 in study both groups of patient :(DM1&DM2) compared with control subjects	38
III.6	Fig. III.6 showed a mean level of Apo B in study both groups of patient :(DM1&DM2) compared with control subjects	39
III.7	Fig. III.7 showed a mean level of Lp(a) in study both groups of patient :(DM1&DM2) compared with control subjects	40

LIST OF TABLES

Table	Title	Page
III.1.	Table III.1 showed mean age of study groups (DM1, DM2 and control (subjects	31
III.2	Table III.2 showed gender of study groups (DM1, DM2 and control (subjects	31
III.3	Table III.3 showed gender of a patient	31
III.4	Table III.4 showed a mean level of glucose in study both groups of patient (DM1&DM2) compared with control subjects	32
III.5	Table III.5 showed a mean level of total cholesterol in study both groups of patient (DM1&DM2) compared with control subjects	33
III.6	Table III.6 showed a mean level of Triglyceride in study both groups of patient (DM1&DM2) compared with control subjects	34
III.7	Table III.7 showed a mean level of VLDL in study both groups of :patient (DM1&DM2) compared with control subjects	34
III.8	Table III.8 showed a mean level of HDL in study both groups of patient (DM1&DM2) compared with control subjects	36
III.9	Table III.9 showed a mean level of LDL in study both groups of patient :(DM1&DM2) compared with control subjects	36
III.10	Table III.10 showed a mean level of Apo A1 in study both groups of patient (DM1&DM2) compared with control subjects	38
III.11	Table III.11 showed a mean level of Apo B in study both groups of patient (DM1&DM2) compared with control subjects	39
III.12	Table III.12 showed a mean level of Lp(a) in study both groups of :patient (DM1&DM2) compared with control subjects	40
III.13	Table III.13 explained the relation between the mean of both gender and age groups of Lipo(a) in study both group of patients	41
III.14	Table III.14 explained the significance correlation between Apo A1 (and HDL in study groups (patients and control	41
III.15	Table III.15 explained the significance correlation between LDL, Apo (B and Lipo(a) in study group (patients and control	41

Abbreviations:

	T
LDL	Low Density Lipoprotein.
HDL	High Density Lipoprotein.
VLDL	Very Low Density Lipoprotein.
Apo A1	Apolipoprotein A1.
Apo B	Apolipoprotein B.
Lp(a)	Lipoprotein(a).
CVD	Cardio Vascular Disease.
CHD	Coronary Heart Disease.
DM1	Diabetes Mellitus type one.
DM2	Diabetes Mellitus type two.
IDDM	Insulin Dependant Diabetes Mellitus.
NIDDM	Non Insulin Dependant Diabetes Mellitus.
DKA PVD	Diabetic ketoacidosis.
PLG	Peripheral Vascular Disease.
LCAT	Plasminogen.
WHO	Lecithin - Cholesterol - Acyl Transferase. World Health Organization.
GOD .	Glucose Oxidase
POD	Peroxides.
PAP	Phenol 4-Amino Phenazone.
O2 H2O2	Oxygen.
TC	Hydrogen Peroxide.
TG	Total Cholesterol.
n	Triglyceridenumber
M	Male
F	Female